Despite the recent availability of complete genome sequences of tumors from thousands of patients, isolating disease-causing (driver) non-coding mutations from the plethora of somatic variants is notoriously challenging, and only a handful of validated examples exist. By integrating whole-genome sequencing, gene expression, chromatin accessibility, and genetic data from TCGA, we identified 301 non-coding somatic mutations that affect gene expression in cis. These mutations cluster into 36 hotspot regions with diverse molecular mechanisms of gene expression regulation. We further show that these mutations have hallmark features of noncoding drivers; namely, that they confer a positive selection on growth, functionally disrupt transcription factor binding sites, and contribute to disease progression reflected in decreased overall patient survival.
Introduction
Identification of somatic mutations that contribute to tumorigenesis is an essential step to understanding disease prognosis and developing therapies [1] [2] [3] . Despite extensive exome and genome sequencing efforts, a substantial proportion of causal or driver mutations (called drivers from here on) are thought to be unknown [4] [5] [6] [7] . On average, 22 .2% of tumor samples within each cancer type do not harbor coding mutations in any of 144 common driver genes 8 . Moreover, since multiple drivers are typically involved 9 , even tumors with well-characterized mutations likely harbor additional causal alterations [9] [10] [11] [12] . Mutations in cis-regulatory elements (CREs) are postulated to comprise a large fraction of the undiscovered drivers 12 . However, despite the availability of hundreds of complete tumor genomes, only a few non-coding drivers have been experimentally validated (Table S2 ).
Distinguishing drivers from passengers outside coding regions requires overcoming several known challenges: the search space is orders of magnitude larger, functional impact cannot be predicted from amino acid changes (especially gain-of-function hotspots), mutation rates are higher 13 , and positive selection pressure on relative growth is relaxed. These challenges have been partially overcome by associating mutations with alterations to transcription factor binding sites [14] [15] [16] , altered mRNA abundance 17 , clinical data 14, 18 , and evolutionary conservation [19] [20] [21] [22] . Combinations of these features have also been weighed to prioritize putative drivers and determine significant mutational hotspots 14, [21] [22] [23] .
Since the tumorigenic role of a noncoding driver is likely exerted through a cis-change in gene expression 24 , mapping genes whose expression is impacted by cis-acting regulatory effects has significant promise. Allele-specific expression (ASE), where one allele of a gene is more highly expressed than the other, is a powerful approach for detecting cis-regulatory effects, since trans-regulatory effects impact both alleles equally 25 . By comparing ASE in tumors to matched normal ASE ("diffASE"), it is further possible to distinguish somatic from germ-line effects.
Ongen et al. applied this approach to identify 71 putative driver genes in colorectal cancer 26 . In practice, however, the sparse availability of matched tumor and normal gene expression and genetic data poses a significant limitation. Just 7.7% of TCGA tumor samples have matched normal RNA-Seq data (Fig. S1A ).
Here we show that the vast majority of differential ASE is acquired in tumors, enabling us to dispense with the matched normal requirement and expand our survey 13-fold. We interrogated all whole-genome sequenced noncoding somatic mutations across 1,165 TCGA patients and identified 36 novel regulatory driver hotspots on the basis of robust association with ASE in tumors. The driver role of these mutations is further supported by elevated variant allele frequencies, functional disruption of transcription factor binding sites, and negative association with overall patient survival. This functional catalog of novel noncoding features significantly expands our knowledge of noncoding tumor driver biology.
Survey of Breast Invasive Carcinoma (BRCA) reveals that >98% of differential ASE is due to ASE in tumor We initially focused on BRCA since it is the cancer type with the largest set of matched tumor and normal data accompanied by whole genome sequence (WGS) in TCGA ( Fig.   S1A ). Measuring ASE relies on counting RNA-Seq reads that map over heterozygous single nucleotide polymorphisms (SNPs) (Fig. 1A) detected by genotyping arrays. To maximize our sensitivity, we first imputed and phased SNPs using the 1000 Genome haplotypes 27 (Fig. 1A) , which on average increases the number of informative SNPs 5-fold. This is more accurate than relying on WGS where sufficient coverage is not always available ( Fig. S1B ). Moreover, falsepositive SNPs have a disproportionately high impact on estimates of ASE since all reads are assigned to one haplotype. Phasing also allowed us to combine allelic counts across SNPs within the same gene 28 (and see Methods for more details). We observed extensive diffASE in BRCA ( Fig. 1B) .
Strikingly, nearly all of the diffASE can be attributed to an increase of ASE in tumors relative to matched controls ( Fig. 1B) . We reasoned that this trend may be due to higher clonality of tumors relative to matched normal tissue which would be expected to be more complex. We first considered whether loss of heterozygosity (LOH) may be a confounding factor. We reasoned that since all BRCA tumors are female, a comparison of allelic expression between autosomes to the X-chromosome could illuminate the contribution of clonality. X-chromosomes are randomly inactivated across cells comprising normal tissue. Comparison with a clone derived from this tissue (where all cells retain monoallelic expression from the same allele) would yield strong diffASE for any expressed gene on chromosome X. If clonality was the dominant source of greater ASE in tumors, we would expect enrichment of highly ranked X-linked genes when evaluated for diffASE. This enrichment would not be expected if LOH was the dominant source. We indeed observed a high enrichment of X-linked genes (66/100) among the top diffASE genes, suggesting that these tumors are highly clonal ( Fig. S1D ). When we performed the analysis of ASE using tumor expression data alone (tumorASE), we observed a recapitulation of >98% of the diffASE events ( Fig. 1C ). Finally, ASE events originating in tumors were not strongly correlated with CNV or methylation ( Fig. 1D , E), which we estimate collectively explain less than 1% of ASE in tumors.
In summary, we believe that altered cis-regulatory mechanisms of gene expression explain the majority of observed ASE in tumors, and that this signal is a valuable starting point for identifying noncoding drivers.
Identification of mutations that explain ASE in tumors
The availability of WGS data for 113 BRCA RNA-seq samples ( Fig. S1A ) allowed us to find specific mutations that are associated, and which may explain, the observed ASE in tumors. We evaluated common mutation callers and implemented a robust filtering scheme to yield high confidence somatic variants (see Methods for details). We then asked whether the presence or absence of these variants near a gene is associated with ASE of that gene across BRCA tumor samples. Unfortunately, using the entire region surrounding a gene did not yield associations that survived multiple test correction, even in this heavily surveyed cancer type. The high proportion of neutral mutations relative to genuine noncoding drivers likely explains this result, and necessitates an enrichment strategy for variants that are likely to have a functional impact.
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The vast majority of previously validated noncoding driver mutations occur in promoters, enhancers, and CTCF binding sites (Table S1 ). As these collectively encompass major sites of transcriptional regulation, we focused on somatic variants within these features and refined them using several publically available annotation resources. To comprehensively map genomic regions where transcription is regulated, we also included an aggregate map of TF binding sites ('ChIPseq'). For the enrichment analysis, we grouped the somatic mutations in promoters, CTCF and TF binding sites by regulatory feature and asked if they were 10kb upstream of a TSS or gene body of a gene exhibiting ASE. Conversely, since enhancers vary by cell type and frequently regulate non-adjacent genes, we used cancer-specific enhancers and regulatory relationships defined by associations between accessible chromatin and changes in gene-expression 29 . Putative drivers were identified by positive correlations between gene-level ASE and somatic regulatory mutations (see Methods). This approach revealed novel non-coding driver mutations regulating genes previously implicated in breast cancer by coding variants as well as altered regulation of novel genes.
Using these features, we found somatic mutations in the regulatory elements of seven genes that are enriched for altered cis-regulation in breast cancer (FDR<=0.9, n=113). These include mutations in the enhancers of EGFR, CDC42EP3 and TIMP3, variants in the promoters of UNC5B, CTCF binding sites of DAAM1 and NOTCH1 as well as TF binding sites near ITPR3 ( Fig. 2A ).
Altered cis-regulation of EGFR is particularly notable as coding mutations in it are among the most common cancer drivers ( Fig. 2B , C) 30, 31 . In the 4 tumors harboring enhancer mutations, dysregulation is evident from the ASE ratio of 3.81 compared to 1.68 in tumors where they are not mutated ( Fig. 2B , P=3.64x10 -3 , Pearson's linear correlation).
Somatic mutations in regulatory features are enriched for gene-level ASE in diverse tumors
We applied our pipeline to 12 cancer types that had a sufficient number of matched WGS, RNA-Seq, genotyping, and chromatin accessibility data (derived by ATAC-seq 29 ) ( Fig. S1A ). We identified 36 putative driver hotspots consisting of 301 mutations ( Fig. 3 , Table S1 ), which we will collectively refer to as the "novel driver candidates". Notable examples of novel drivers based on prevalence include the enhancers of ME3 in colon adenocarcinoma (COAD; 13.2%; n=7/53), the CTCF bound regions of CBLB in acute myeloid leukemia (LAML; 12.2%; n=5/41) and the CTCF bound region of SEMA4D in lung squamous cell carcinoma (LUAD; 11.5%; n=26/226).
Interestingly dysregulation of COL4A1 was found in two cancer types, including LUAD and COAD ( Table 1 and S1). The majority of genes impacted by our novel drivers have been implicated previously in cancer and compelling cases for their driver mechanistic roles are explored further below (see Discussion).
Novel driver candidates have elevated variant allele frequencies By definition, driver
mutations confer a selective advantage to the cells in which they occur. Variant allele frequency (VAF) measures the fraction of alleles in a sample in which the variant is present. Hence, if a mutation confers a selective advantage to the cell in which it occurs, its VAF would be higher, on average, than passenger mutations that arose coincidentally. A corollary being that mutations with increased VAF occurred early enough during tumor evolution for this selective advantage to manifest as increased VAF. To ask whether driver mutations conferred a selective advantage, we compared the normalized VAF of all putative drivers to all non-coding mutations that were not enriched for ASE (P>0.5). As a positive control we used known coding driver mutations 8 . As expected, we found that the VAF of known coding drivers (n=116) was, on average, higher than background mutations in coding regions (P-value=7.5×10 -6 , n=2,971). Importantly we found that the VAF of our novel driver candidates was also higher ( Fig. 4A ), an effect that is independent of CNV based on the stable ratio of adjacent heterozygous SNPs ( Table 1 and S1).
Novel driver candidates disrupt transcription factor binding motifs
To begin to explore the mechanisms through which our driver mutations may be acting, we asked whether they may impact TF binding. TF binding affinities are typically represented by a generalized position-weight matrix (PWM) that represents a motif and a probability of observing any of the four bases at each position in that motif. These probabilities are typically constructed from observed frequencies of genuine binding events and can be represented as bit-scores. A bit-score of 2 implies that a particular base is always found at that position. The challenge with relying on PWMs exclusively to identify transcription factor binding is that there is typically insufficient information to distinguish genuine binding sites from the many possible motif sequence matches in the genome. To enrich for genuine binding sites we only considered mutations in our functionally annotated regions and required that mutations exceed a minimal degree of evolutionary conservation (Phastcons>0.05; 32 ).
If our driver mutations were causing ASE by disrupting binding at one of the alleles, we would expect to see a greater impact on the difference in bit scores (i.e. delta-bit) in ASE (driver) vs. non-ASE (background) mutations. We observed this effect in our promoter and CTCF features ( Fig. 5 ). It is also possible that improving binding (i.e. a positive delta-bit) could cause ASE, although we did not see evidence for this which may be due to power constraints stemming from "functional gain" in binding being less frequent than "functional loss".
Novel driver candidates correlate with reduced survival To assess the impact of the putative drivers on patients, we asked how they effected survival. For this analysis, we grouped patients across all cancer types and features to enhance statistical power. Since each cancer type alone yields vastly different survival outcomes 33 , we constructed carefully matched background sets with cancer type proportions constrained (see Methods). The overall survival (OS) of patients whose tumors were driven by any of the 36 non-coding drivers ( Table 1 and S1) was worse than patients with a matched mutation burden not associated with ASE. The lower OS is also evident when comparing non-coding driver carriers to background versus 5,000 random subsets of the entire cohort ( Fig. 6A ). The negative impact of these drivers is clear when visualizing survival of patients carrying the non-coding drivers to one random subset of the whole dataset ( Fig. 6B ). Next we compared the impact of mutations in different classes of regulatory elements in different cancers on survival. The impact of driver mutations in promoters as well as CTCF and TF binding sites was predominantly negative (Fig. 6C ). These analyses indicate that mutation of distinct classes of regulatory features may contribute to disease progression.
Discussion
Our 36 mutation hotspots associated with ASE significantly expand the landscape of noncoding cancer drivers. The majority of our findings are novel, although there is parital overlap with previous noncoding driver discoveries. For example, we found enriched cis-regulatory mutations in the CTCF binding sites of DAAM1 and NOTCH1 in BRCA. DAAM1 is a member of the formin protein family activated by Dishevelled binding 34 . It regulates cytoskeletal dynamics through its control of linear actin assembly 35 . Regulatory mutations in DAAM1 were recently implicated in invasiveness of melanoma 36 . Similarly, mutations in the 3' UTR of NOTCH1 were previously implicated in chronic lymphocytic leukaemia 23 . Our findings also overlap previous reports in that somatic mutations in other regulatory regions of the same genes in the same type of cancer have been implicated as drivers. For example, mutations in the splice-acceptor site of GATA3 were previously implicated in LUAD 37 . Here we implicated promoter mutations in GATA3 in LUAD. This overlap suggests that the consequences of mutated regulatory features may overlap in these cases, and that combining the association of distinct features that regulate the same gene may increase sensitivity.
Many of the genes impacted by noncoding drivers discovered here ( Table 1 and S1) have been previously implicated in cancer biology. The BRCA hotspots illustrate how driver roles clearly tie into the established functions of the dysregulated genes. Binding of a variety of ligands to EGFR promotes cell survival and proliferation via ERK signaling, and its mutation is one of the most common cancer drivers 30, 31 . NOTCH1 is a key mediator of signaling between adjacent cells.
It is essential in specification of a variety of cell types, maintaining tissue homeostasis and its mutation is a highly prevalent driver in certain cancers, such as T-cell Acute Lymphoblastic Leukemia 38 . ITPR3 mediates the release of intracellular calcium in response to IP3 39 . It was recently implicated as the target of the tumor suppressor BAP1 that triggers apoptosis following exposure to genotoxic stress 40 . UNC5B is a netrin family receptor that mediates guidance of the vascular system as well as other cell types 41, 42 . It encodes a repulsive netrin whose disruption results in aberrant extension, branching and navigation of affected cells 41 . CDC42EP3 is a Cdc42 effector that regulates septin organization through binding to septin GTPases 43, 44 . The tumor growth promoting activity of cancer-associated fibroblasts requires CDC42EP3 45 . Finally, TIMP3
is an inhibitor of matrix metalloproteinases whose upregulation suppresses tumor growth 46 .
In contrast with previous reports, somatic mutations in regulatory features, not CNVs or differential methylation, underlie the majority of altered cis-regulation in tumors 47 . Somatic variants in non-coding regions that are enriched for altered cis-regulation were found in 13.4% of the tumors analyzed. This high-prevalence is predicted by multi-hit models as well as divergent phenotypes between tumors with common known drivers. While many of the associations involve genes thought to be involved in tumorigenesis, the implication of specific mutations and regulatory features is novel. Indeed, we are not aware of any of the specific mutated regulatory features reported here previously being implicated as drivers of tumorigenesis.
Although TCGA and other emerging cancer data now include >1000 available genomes, illuminating the complete set of noncoding drivers will require a substantially broader collection.
Even with the approach employed here of focusing on functional somatic variants with underlying evidence of gene expression regulation, we found ourselves limited by statistical power, especially in cancer types with fewer than 100 genomes. Deeper genome sequencing with longer reads will also improve driver detection sensitivity by enabling phasing of mutations with the direction of ASE. This would allow more evidence to be used to prioritize genuine drivers (e.g. disruption of an activating transcription factor binding site should reduce expression of that allele). This was generally not possible with the current available data since accurate phasing of somatic variants more than a few hundred base pairs away from the gene would require long-read technology or much deeper coverage. Improved matching of the regulatory features to each cell type will also improve sensitivity. When possible, cellular context was prioritized throughout these analyses to account for context-specific aspects of gene-regulation. For example, enhancers were matched to the cancer type being analyzed 29 , and each cancer was separately analyzed in parallel, however, enhancer to gene maps are still incomplete and will no doubt improve with more chromatin accessibility readouts expand. In any case, we believe our approach here, made freely available as a dockerized pipeline (see Methods) will be a powerful tool for taking advantage of these emerging resources and building on our discoveries.
Methods
Genotyping and imputation Genome-wide Affymetrix 6.0 genotype array datasets from normal blood samples were downloaded as Birdseed files from GDC Legacy Archive (https://portal.gdc.cancer.gov/legacy-archive/search/f) for all 5,875 patients from 12 cancer types. Among these patients, only the 1,165 where tumor RNA-seq and matched tumor/normal WGS data were available were included in the downstream association between gene-level ASE and mutation occurrence (see Fig. S1A ). These datasets were annotated with Affymetrix annotation files and converted into base-level genotypes. To minimize allelic mapping bias we excluded SNPs with more than 2 polymorphisms or those where 2 SNPs conflicted at the same site on the same strand in phased 1000 Genomes Project Phase1 v3 data. Affymetrix 6.0 arrays genotype nearly 1 million SNPs. Typically ~25% of these sites are heterozygous and only a small fraction fall within expressed regions (mean=12,468). To increase the number of SNPs available to resolve ASE, we imputed and phased genotypes as previously described in Babak and DeVeale et al. 28 . In brief, genotyping data were transformed into PLINK binary format and subjected to pre-phasing with Shape-IT software (v2.r790) 48 using the 1000 Genomes Project Phase1 v3 data as the reference, then imputed and phased using Impute2 software (v2.3.2) 27 . We Gene-level ASE To generate gene-level ASE ratios, heterozygous SNPs in each individual were mapped to a custom human transcript track generated by aggregating Ensembl (v80), UCSC and NCBI transcripts. Gene-level ASE was calculated by summing allelic counts from all heterozygous SNPs within the same haplotype by gene. Notably, the increased number of expressed heterozygous SNPs provided by imputation increased the proportion of genes assayable (≥50 reads) for gene-level ASE from 50% to ~90%.
Differential ASE To distinguish somatic from physiological ASE (random monoallelic silencing, imprinting etc.) we performed differential (diff)ASE analysis. diffASE is the difference in genelevel allelic bias between the normal and the tumor expression profiles (e.g. 50:50 versus 60:40, chi-squared p = 0.1). An event was either tumor-or normal-specific, depending on which sample deviated further from 50:50 allelic expression. diffASE events where the ratio between two alleles is more skewed in the tumor than in the normal are of primary interest. The FDR generated with 10,000 permutations of ASE reads from tumor and normal samples for each gene. In cases where matched normal RNA-seq was not available, 'tumorASE' was assessed relative to the binomial distribution (P<0.001). The FDR was assessed with 10,000 permutations of the reads at each gene randomly drawn from all samples. To compare the outcome of diffASE and tumorASE, we filtered for genes ≥50 reads in at least half of both the tumor and normal samples. Extensive overlap between diffASE events (chi-squared P<0.001) and tumorASE (binomial distribution P<0.001),
indicates that >98% of diffASE originates in tumors (Fig. 1C ). Thus we included gene-level ASE from tumor RNA-seq without a matched normal sample to dramatically increase the sample size ( Fig. S1A ).
Mutation calling
To identify somatic mutations, we used Varscan in conjunction with custom filters. WGS data of 12 cancer types were downloaded from GDC Legacy Archive as 1,165 matched tumor/normal BAM files (extensive sample information is available in Table S3 ). We required that WGS samples had matched tumor/normal files, as well as corresponding genotype array, copy-number, and tumor RNA-seq data for inclusion. Additionally, only WGS tumor/normal pairs aligned to the GRCh37 reference build (hg19) were included in our analysis.
For SKCM, we used metastatic tumor samples (sample type 6 in the TCGA database), and primary tumor samples for the remaining cancer types (sample type 1). The sequence read counts at each site were obtained from WGS BAM files aligned to the GRCh37-lite human reference genome with the SAMtools 49 mpileup. The base quality alignment (BAQ) computation of SAMtools was turned off with the parameter '-B' as it is too stringent for variant calling, and reads with mapping quality > 0 was set with '-q 1'. Single nucleotide substitutions, insertions and deletions were simultaneously called using Varscan2 somatic caller 50 . Data were processed using a 1,052-core Linux cluster at the High-Performance Computing Virtual Laboratory (HPCVL) (Kingston, Ontario).
Somatic mutations were focused on single-nucleotide substitutions, as well as small insertions and deletions ( Fig. S2D) , not structural variations. Somatic mutations generated by Varscan2 were initially filtered with two criteria: (1) a minimum read depth of 10 for both the tumor and matched normal, and (2) alleles with a mutation frequency exceeding 0.1 in tumor but less than 0.1 in matched normal (Fig. S2A ). However, since ~60% of the mutations called with this approach were rare germline SNPs ( This optimization supported use of an AAF ≤ 2% in matched normal samples since the fraction of dbSNPs increased when the AAF was higher ( Fig. S2C ). It also supported a requirement that the AAF exceed 10% in tumors. Finally, we required that the difference between the AAF in tumors and matched normal samples exceed 30% based on the optimization (Fig. S2B ). Only 12.8% of variants passed this 30% threshold but it was effective in decreasing the fraction of dbSNPs included in the association as variants (Fig. S2C ). Finally, we filtered all known dbSNPs from the mutations that passed these filters.
Effect of copy number variations on gene-level ASE
To evaluate the effect of CNV on genelevel ASE, raw Affymetrix CNV data were downloaded from GDC Legacy Archive for 1,091 BRCA tumors. CNV data were then annotated with 'GenomeWideSNP_6.cn.na35.annot.csv.zip' downloaded from Affymetrix home page and mapped to Ensembl genes. Gene-level CNV signals were calculated by averaging the signals of all CNVs mapped to the gene. Finally, the somatic CNV signal for each gene was correlated with its corresponding value of gene-level allelic imbalance (reads ≥50) to determine the influence of CNV on ASE in tumors. We applied this process to 1,091 tumor ASE and 92 diffASE, calling significant associations between gene-level ASE and CNV signal when P<0.05.
To remove the confounding effect of CNVs among associations between gene-level ASE and regulatory mutations, we assessed the correlation of each gene associated in our analysis with CNV signal. We also determined the association between gene-level ASE and CNV exclusively among driver mutation carriers to differentiate the effect of driver mutations from that of CNV on genelevel ASE. We applied this filter for BRCA and other 11 cancer types, and found that none of driver genes displayed significant association (P<0.05) with CNV when only the samples containing driver mutations were considered.
To ask whether the CNV contributed to the association between mutated regulatory features and ASE of individual genes, we asked if CNV and ASE were correlated for each putative driver ( Table   1 and S1). 30 of 36 drivers were not correlated with CNV. For the 7 genes where there was an association, we asked if it was dependent on CNV. The only putative driver where mutations and CNV coincided was TSHZ2 (STAD). Hence the association between mutations and ASE occurs independent of CNV in 35/36 putative drivers. Even for TSHZ2 (STAD), the mutations in TF binding sites and CNV only coincided in 1 tumor, and the association between mutations and ASE remained significant after excluding it (P=2.2×10 -5 ).
Effect of methylation on gene-level ASE
To determine the effect of methylation on gene-level ASE, we downloaded methylation Beta values for 1,091 BRCA tumors from GDC Legacy Archive. These methylation data were converted into bed format and mapped to Ensembl genes.
The average methylation score was determined for each gene including a 2kb region upstream and downstream of each gene to encompass the promoter. ASE imbalance values were then correlated with average methylation levels on a gene-by-gene basis to determine the influence of methylation on gene-level ASE. This analysis was applied to all genes for 92 tumor/normal RNA-seq samples.
Significant correlations between gene-level ASE and methylation Beta value were called at P<0.05.
Selection of cis-regulatory features
We surveyed major cis-regulatory features for cis-regulatory variants. These included TF binding sites (Encode ChIP-seq peaks clustered V3, 2013) and CTCF binding sites (from GM12878 cell line) both obtained from the UCSC database. We derived a single track of TF binding sites by collapsing multiple ChIP-seq maps of TF binding (Table S4 ).
We also interrogated promoters (Roadmap Project) and cancer-specific enhancers 29 . These were defined based on the presence of peaks: promoters were defined as H3K4me3+ regions (signal in ≥10/127 tissues/cell types from the NIH Roadmap Epigenomics Mapping Consortium), while cancer-specific enhancers were defined by association between accessible chromatin and geneexpression changes in specific cancers 29 . First, the somatic mutations were mapped based on proximity to promoters and enhancers as well as TF and CTCF binding sites. Using these annotations, promoters comprise 1.6% of the genome, enhancers ~1.4% (ranging from 0.8% in LGG to 2.7% in BRCA), TF binding sites 13.2% and CTCF binding 6.0% of the genome. Somatic mutations were binned as present (=1) or absent (=0) among the regulatory features. The overlap among these regulatory features ranges from 0.04% to 85% (Fig. S3A ). For example, CTCF and TF binding sites occupy 20-70% of the enhancer feature, while the enhancers occupy <10% of the CTCF binding sites.
Association of mutations and gene-level ASE
Second, somatic mutations, including single-nucleotide alterations, insertions and deletions were mapped to nearby genes. The genomic coordinates of each gene were defined as beginning 10kb upstream of the TSS and gene body of each gene. These settings were applied to test mutation association within each regulatory region (see Finally, the correlation significance (Pearson r 2 value; coefficient of determination) between a gene's allelic imbalance and mutations in each annotated region was determined with MATLAB.
To obtain robust results we only ran the association when both mutation carriers (n>=3) and noncarriers (n>=3) had gene-level imbalance values derived from summing ≥50 reads from all heterozygous sites. Only ASE events positively correlated with mutations were retained in the analysis to focus on allelic imbalance resulting from dysregulation. All negative correlation were assigned P value =1.
We permutated the data to determine the false discovery rate (FDR) for the association between gene-level ASE and the occurrence of somatic mutations in each genomic feature. For mutations residing in specific genomic regions, all pairs of gene-level ASE and mutations were randomized 1,000 times to generate association P-values that reflect the distribution of the data. The FDR for each gene was then calculated through comparison of the actual association P-value to all genes' minimum P-values derived from 1,000 random permutation as: sum(real P<minimum(1,000 permutations of P-values))/total number of genes. Regulatory features that could be associated with multiple genes were included in all possible associations. When independent mutations were found within the same feature of the same sample, they were collapsed to a single mutation for the association. Finally, if multiple regulatory features were enriched for ASE of the same gene, only the most significant association with the smallest FDR was retained.
VAF VAF was calculated independently for each mutation that we identified in WGS data as the fraction of all sequencing reads covering the variant that were mutated. VAF was z-scaled within each patient using all mutations detected in that patient in order to normalize out the effect of tumor heterogeneity. Noncoding driver and background sets were selected on basis of association with ASE. P>0.5 and FDR=1 were used as criteria for lack of significant association with ASE.
Significance (2-tailed) was assessed using an unpaired t-test for unequal variance.
Survival Analysis Unique patients IDs with predicted noncoding drivers were extracted from
Table S1 (ASE-mutation association FDR<0.5). Clinical data for TCGA was downloaded from BROAD Firehose (https://gdac.broadinstitute.org/) on April 21, 2017. Null distributions of patients were selected on basis of 1) having matching mutations in the same set of features in the same cancer type, 2) being powered to detect ASE (i.e. presence of RNA-seq data and phased SNPs), and 3) association between ASE and mutation having no significance (i.e. FDR=1).
Probability of a difference in survival was assessed using the Kaplan Meier approach with censored data implemented in the MATLAB script KMPLOT 51 . Since P-values are dependent on random selection of background and the limitations above imposed an upper limit on the number of background subjects that fit all criteria. Bootstrapping with 5,000 iterations was conducted to compare with P-values generated from random sets of background comparisons.
Effect on Transcription Factor Binding Sites
The human genome was scanned using HOMER (scanMotifGenomeWide.pl using default settings for 392 motifs in the HOMER package 52 to map putative binding sites for each factor. The default log-odds detection thresholds included with the package were used. Somatic mutations were overlapped with each motif and the difference in bitscores (i.e. "delta-bit" using the PWM) between the reference and mutated bases was calculated, with 2 is the maximum bit-score. Delta-bit scores associated with genes under ASE versus no-ASE were compared. Only single nucleotide substitutions at positions with phastcons scores greater than 0.05 were considered for this analysis. A mutation could be considered more than once if two or more transcription factor binding motifs were present. Note: *Among all 7 genes demonstrating association between ASE and CNV, no genes have tumors carrying driver mutations and CNV coincidently, except for TSHZ2 (STAD) where only one tumor carrying both driver mutation and CNV; however, the association between mutations and ASE remained significant after excluding the tumor (P=2.2×10 -5 ). #When a driver gene doesn't have more than 1 sample harboring CNV for the association test between ASE and CNV, the association is assigned as P = 1. CNV: copy number variation; P: ASE-mutation association P-value; ASE-CNV Assoc P: ASE-CNV association Pvalue; FDR: false discover rate; Carriers: driver mutations carriers. Supplementary Tables   Table S1 . Annotated catalog of the 301 potential driver mutations among 36 putative driver hotspots. Figure S2 
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